Found Clinical Gaps and Limitations: What This Weight-Loss Platform Misses

Found's Business Model and What It Actually Delivers

Found operates as a subscription telehealth platform pairing asynchronous physician consultations with behavioral coaching and, where clinically indicated, prescription medications including GLP-1 receptor agonists. The BCBS partnership expanded access for insured members starting in 2023.

The platform charges $99 to $199 per month for its core service. Medication costs sit on top of that fee. Members complete an intake questionnaire, receive a provider match, and communicate primarily through in-app messaging. This model prioritizes accessibility and scale. It does not prioritize the depth of metabolic evaluation that the Endocrine Society's 2024 Clinical Practice Guideline on pharmacological management of obesity recommends before initiating GLP-1 therapy.

The guideline specifies baseline HbA1c, fasting lipid panel, hepatic function tests, and renal function assessment before prescribing semaglutide or tirzepatide. Found's publicly available intake process does not require these labs prior to prescribing. A platform can be legitimate and still leave clinical gaps wide enough to matter.

Gap 1: No Published Outcome Data

Found has not published peer-reviewed efficacy data from its own patient population. Zero randomized trials. Zero retrospective cohort analyses. Zero real-world evidence studies in indexed journals.

This matters because telehealth obesity platforms face unique adherence challenges. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight reduction with semaglutide 2.4 mg at 68 weeks under protocol-mandated monthly visits, dietary counseling from registered dietitians, and structured exercise guidance. Translating those results to an asynchronous messaging model with variable coaching credentials requires evidence that Found has not provided.

Ro, a competitor platform, published retrospective data in 2024 showing 12.2% weight loss at 12 months in its GLP-1 cohort. Calibrate published 15% average weight loss at 12 months with intensive metabolic protocols. Found's marketing references STEP-1 and SURMOUNT-1 trial data without disclosing how its own patients perform relative to those benchmarks.

The absence of outcomes transparency is not merely an academic concern. The FDA's 2023 guidance on prescription drug advertising explicitly warns against implying trial-level results when real-world performance has not been validated in the advertising platform's specific care delivery model.

Gap 2: Metabolic Monitoring Falls Below Guidelines

The Endocrine Society's 2024 guideline recommends the following monitoring schedule for patients on GLP-1 receptor agonists for obesity: fasting glucose and HbA1c at baseline and every 3 months during titration, lipid panel at baseline and 6 months, hepatic transaminases at baseline and if symptoms develop, and renal function for patients on concomitant medications affecting GFR.

Found's standard protocol, as described in its help documentation and member testimonials, does not require any baseline labs before initiating therapy. Members self-report medical history. Providers may order labs but are not required to by the platform's care pathways.

This creates a specific risk. A patient with undiagnosed type 2 diabetes (prevalence: 11.6% of U.S. adults per CDC 2024 data) could begin semaglutide without baseline HbA1c documentation, making it impossible to track glycemic improvement or detect hypoglycemia risk from rapid glucose reduction.

Dr. Caroline Apovian, co-author of the Endocrine Society guideline, stated in a 2024 interview with Obesity Medicine Association: "Any prescriber initiating GLP-1 therapy without baseline metabolic labs is practicing below the standard of care, regardless of the delivery platform."

Gap 3: Restricted Medication Formulary

Found's publicly listed medication options include semaglutide (Wegovy/Ozempic), tirzepatide (Zepbound/Mounjaro), naltrexone-bupropion (Contrave), and topiramate-phentermine (Qsymia). This covers the most prescribed options but excludes several FDA-approved alternatives.

Missing from Found's formulary:

Setmelanotide (Imcivree), approved for rare genetic obesity conditions affecting MC4R pathway signaling. Gelesis100 (Plenity), a non-systemic hydrogel approved for BMI 25-40. Liraglutide 3.0 mg (Saxenda), which remains relevant for patients who cannot tolerate semaglutide's longer half-life or prefer daily dosing control.

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm emphasizes individualized medication selection based on comorbidity profile, contraindications, and patient preference. A platform with a narrow formulary cannot execute this algorithm fully.

For patients with binge eating disorder comorbidity, lisdexamfetamine (Vyvanse) carries FDA approval for moderate-to-severe BED and produces 5-7% weight loss as a secondary benefit. Found does not prescribe controlled stimulant medications. This gap forces patients with obesity-BED overlap to maintain a separate psychiatric prescriber, fragmenting care.

Gap 4: Asynchronous Care Model Limitations

Found's primary communication channel is asynchronous in-app messaging. Scheduled video or phone visits are available but not the default care pathway. The SURMOUNT-1 trial (N=2,539) that produced 20.9% weight loss with tirzepatide 15 mg included 23 scheduled clinic visits over 72 weeks.

Asynchronous care introduces latency between symptom reporting and clinical response. GLP-1 agonists carry a 1-3% incidence of acute pancreatitis symptoms requiring same-day clinical assessment per FDA prescribing information for Wegovy. A patient experiencing epigastric pain radiating to the back who messages their Found provider at 9 PM may not receive a response until the following business day.

The platform's model also limits physical examination capability. Injection-site reactions, thyroid nodule assessment (relevant given the boxed warning for medullary thyroid carcinoma risk in rodent studies), and abdominal examination for gallbladder disease all require hands-on evaluation that messaging cannot replicate.

Dr. Fatima Stanford, obesity medicine physician at Massachusetts General Hospital, noted in a 2024 JAMA viewpoint: "Telehealth expands access, but the pendulum has swung too far when platforms eliminate synchronous physician encounters entirely from the obesity treatment pathway."

Gap 5: No Structured Discontinuation Protocol

The STEP-4 trial demonstrated that patients who discontinued semaglutide after 20 weeks of treatment regained two-thirds of lost weight within 48 weeks. Weight regain after GLP-1 discontinuation is the rule, not the exception.

Found's program does not publicly describe a structured discontinuation or maintenance protocol. Members who achieve goal weight, lose insurance coverage, or experience financial strain face an unguided transition. The platform's incentive structure (monthly subscription revenue) does not align with helping patients step down from therapy.

A comprehensive obesity program should include: dose tapering protocols, transition to lower-cost maintenance medications (metformin, naltrexone-bupropion), intensification of behavioral interventions during the peri-discontinuation period, and scheduled weight monitoring for 12-24 months post-cessation. The Obesity Medicine Association's 2024 position statement classifies these elements as minimum standards for GLP-1 prescribing programs.

Found offers "continued coaching" as its maintenance solution. Coaching without pharmacological transition planning and structured monitoring does not match what the evidence shows patients need during this high-risk period.

Gap 6: Behavioral Coaching Credential Variability

Found employs "health coaches" whose credential requirements are not publicly standardized. The platform does not guarantee access to registered dietitians (RDs), certified diabetes educators (CDESs), or licensed clinical psychologists.

This distinction matters clinically. The Look AHEAD trial (N=5,145) achieved sustained weight loss with intensive lifestyle intervention delivered by credentialed teams including RDs and exercise physiologists. A health coach with a weekend certification from a non-accredited program does not replicate this intervention intensity.

Behavioral coaching for obesity requires competency in cognitive behavioral therapy for eating behavior, motivational interviewing validated in obesity-specific RCTs, medical nutrition therapy that accounts for GLP-1 medication effects on gastric motility and appetite, and exercise prescription modified for musculoskeletal limitations common at higher BMI.

Found's coaching offering may include some of these elements for some patients. The "may" is the problem. Standardization of behavioral intervention delivery defines the difference between a clinical program and a wellness app with prescribing capability.

How Found Compares to Guideline-Based Care

The AACE 2023 comprehensive obesity management algorithm specifies four pillars: nutrition therapy by an RD, physical activity prescription, behavioral intervention (CBT-based), and pharmacotherapy with ongoing monitoring. Found delivers pillar four (pharmacotherapy) with partial elements of pillars two and three. Pillar one (credentialed nutrition therapy) remains unconfirmed in their standard offering.

Comparator platforms like Calibrate require baseline labs, mandate quarterly lab monitoring, employ RDs for nutrition counseling, and have published 12-month outcomes. Sequence requires metabolic blood panels at intake and months 3, 6, and 12. These platforms charge similar or higher monthly fees but deliver measurably more clinical infrastructure.

Found's advantage is access speed and lower friction. A patient can potentially receive a GLP-1 prescription within days of signing up. For some patients, particularly those with BMI >40 and prior failed attempts at lifestyle intervention alone, rapid medication access may provide net clinical benefit even with monitoring gaps. The WHO 2024 obesity guideline acknowledges that treatment delay itself carries metabolic risk.

The question is not whether Found is legitimate. It is. The question is whether its care model meets the standard that current evidence and guidelines establish for safe, effective, sustained obesity pharmacotherapy. On multiple measurable dimensions, it falls short.

What Patients Should Verify Before Enrolling

Patients considering Found should request: confirmation that baseline labs (HbA1c, lipid panel, CMP) will be ordered before medication initiation, the credentials of their assigned behavioral coach, the platform's protocol for urgent symptom evaluation (pancreatitis, gallbladder disease, severe GI symptoms), a written plan for what happens if they need to discontinue GLP-1 therapy, and whether their specific insurance plan covers medication costs in addition to the platform fee.

Any platform that cannot provide clear answers to these five questions is operating below the standard of care outlined in the Endocrine Society's 2024 clinical practice guideline for obesity pharmacotherapy.